<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcpsychiatry&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Psychiatry - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcpsychiatry/</link>
        <description>The latest research articles published by BMC Psychiatry</description>
        <dc:date>2012-05-31T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/55" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/54" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/53" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/52" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/51" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/50" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/49" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/48" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/47" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/12/46" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/55">
        <title>Family Functioning in the Aftermath of a Natural Disaster</title>
        <description>Background:
Increased understanding of the complex determinants of adverse child mental health outcomes following acute stress such as natural disasters has led to a resurgence of interest in the role of parent psychopathology and parenting. The authors investigated whether family functioning in the post-disaster environment would be impaired relative to a non-exposed sample and potential correlates with family functioning such as disaster-related exposure and child posttraumatic mental health symptoms.
Methods:
Three months after a category 5 tropical cyclone in north Queensland, Australia, school-based screening was undertaken to case identify children who may benefit from a mental health intervention. Along with obtaining informed consent, parents completed a measure of family functioning.
Results:
Of 145 families of children aged 8 to 12 years, 28.3% met criteria for dysfunction on the Family Adjustment Device, double the frequency in a community sample. The dysfunction group was significantly more likely to have experienced more internalising (anxiety/depression) symptoms. However, in an adjusted logistic regression model this group were not more likely to have elevated disaster-related exposure nor did children in these families validate more PTSD symptoms.
Conclusions:
The implications of post-disaster discordant family functioning and possible different causal pathways for depressive and PTSD-related symptomatic responses to traumatic events are discussed.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/55</link>
                <dc:creator>Brett McDermott</dc:creator>
                <dc:creator>Vanessa Cobham</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:55</dc:source>
        <dc:date>2012-05-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-55</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-55-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>55</prism:startingPage>
        <prism:publicationDate>2012-05-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/54">
        <title>Evaluation of behavioral changes and subjective 
distress after exposure to coercive inpatient 
interventions</title>
        <description>Background:
There is a lack of evidence to underpin decisions on what constitutes the most effective and least restrictive form of coercive intervention when responding to violent behavior. Therefore we compared ratings of effectiveness and subjective distress across four types of coercive interventions.
Methods:
Effectiveness was assessed through ratings of patient behavior immediately after exposure to a coercive measure and 24 hours later. Subjective distress was examined using the Coercion Experience Scale at debriefing. Regression analyses were performed to compare these outcome variables across the four types of coercive interventions.
Results:
Using univariate statistics, no significant differences in effectiveness and subjective distress were found between the groups, except that patients who were involuntarily medicated experienced significant less isolation during the measure than patients who underwent combined measures. However, when controlling for the effect of demographic and clinical characteristics, significant differences on subjective distress between the groups emerged: involuntary medication was experienced as the least distressing overall and least humiliating, caused less physical adverse effects and less sense of isolation. Combined coercive interventions, regardless of the type, caused significantly more physical adverse effects and feelings of isolation than individual interventions.
Conclusions:
In the absence of information on individual patient preferences, involuntary medication may be more justified than seclusion and mechanical restraint as a coercive intervention. Use of multiple interventions requires significant justification given their association with significant distress.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/54</link>
                <dc:creator>Irina Georgieva</dc:creator>
                <dc:creator>Cornelis Mulder</dc:creator>
                <dc:creator>Richard Whittington</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:54</dc:source>
        <dc:date>2012-05-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-54</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-54-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>54</prism:startingPage>
        <prism:publicationDate>2012-05-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/53">
        <title>Attitudes toward Concordance in Psychiatry: A comparative, cross-sectional study of psychiatric patients and mental health professionals</title>
        <description>Background:
Concordance and Shared Decision-Making (SDM) are considered measures of the quality of care that improves communication, promotes patient participation, creates a positive relationship with the healthcare professional, and results in greater adherence with the treatment plan.This study compares the attitudes of 225 mental health professionals (125 psychiatrists and 100 psychiatry registrars) and 449 psychiatric outpatients towards SDM and concordance in medicine taking by using the &quot;Leeds Attitude toward Concordance Scale&quot; (LATCon).
Results:
The internal consistency of the scale was good in all three samples (Cronbach&apos;s alpha: patients=0.82, psychiatrists=0.76, and registrars=0.82). Patients scored significantly lower (1.96+/-0.48) than professionals (P&lt;.001 in both cases), while no statistically significant differences between psychiatrists (2.32 +/- 0.32) and registrars (2.23 +/- 0.35) were registered; the three groups showed a positive attitude towards concordance in most indicators. Patients are clearly in favor of being informed and that their views and preferences be taken into account during the decision-making process, although they widely consider that the final decision must be the doctor&apos;s responsibility. Among mental health professionals, the broader experience provides a greater conviction of the importance of the patient&apos;s decision about treatment.
Conclusions:
We observed a positive attitude towards concordance in the field of psychotropic drugs prescription both in professionals and among patients, but further studies are needed to address the extent to which this apparently accepted model is reflected in the daily practice of mental health professionals.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/53</link>
                <dc:creator>Carlos De las Cuevas</dc:creator>
                <dc:creator>Amado Rivero-Santana</dc:creator>
                <dc:creator>Lilisbeth Perestelo-Pérez</dc:creator>
                <dc:creator>Jeanette Pérez-Ramos</dc:creator>
                <dc:creator>Pedro Serrano-Aguilar</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:53</dc:source>
        <dc:date>2012-05-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-53</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-53-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>53</prism:startingPage>
        <prism:publicationDate>2012-05-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/52">
        <title>Bipolar disorders and Wilson&apos;s disease</title>
        <description>Background:
The aim of this study was to determine the risk for Bipolar Disorder (BD) in Wilson&apos;s disease (WD) and the measure the impaired Quality of Life (QL) in BD with WD using standardized psychiatric diagnostic tools and a case control design.
Methods:
This was a case control study. The cases were 23 consecutive patients with WD treated at the University Hospital in Cagliari, Italy, and the controls were 92 sex- and age-matched subjects with no diagnosis of WD who were randomly selected from a database used previously for an epidemiological study. Psychiatric diagnoses according to DSM-IV criteria were determined by physicians using structured interview tools (ANTAS-SCID). QL was measured by means of SF-12.
Results:
Compared to controls, WD patients had lower scores on the SF-12 and higher lifetime prevalence of DSM-IV major depressive disorders (OR?=?5.7, 95% CI 2.4-17.3) and bipolar disorders (OR?=?12.9, 95% CI 3.6-46.3). BD was associated with lower SF-12 in WD patients.
Conclusions:
This study was the first to show an association between BD and WD using standardized diagnostic tools and a case control design. Reports in the literature about increased schizophrenia-like psychosis in WD and a lack of association with bipolar disorders may thus have been based on a more inclusive diagnosis of schizophrenia in the past. Our findings may explain the frequent reports of loss of emotional control, hyperactivity, loss of sexual inhibition, and irritability in WD patients. This study was limited by a small sample size.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/52</link>
                <dc:creator>Mauro Giovanni Carta</dc:creator>
                <dc:creator>Orazio Sorbello</dc:creator>
                <dc:creator>Maria Francesca Moro</dc:creator>
                <dc:creator>Krishna Bhat</dc:creator>
                <dc:creator>Enrico Demelia</dc:creator>
                <dc:creator>Alessandra Serra</dc:creator>
                <dc:creator>Gioia Mura</dc:creator>
                <dc:creator>Federica Sancassiani</dc:creator>
                <dc:creator>Mario Piga</dc:creator>
                <dc:creator>Luigi Demelia</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:52</dc:source>
        <dc:date>2012-05-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-52</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-52-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>52</prism:startingPage>
        <prism:publicationDate>2012-05-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/51">
        <title>Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data</title>
        <description>Background:
To treat acute schizophrenia, a long-acting injectable antipsychotic needs a rapid onset of action and therapeutic profile similar to that of oral agents. The present post-hoc analyses compared results from a randomized, double-blind, placebo-controlled trial of olanzapine long-acting injection (LAI) for acute schizophrenia with those observed in similarly designed trials of oral olanzapine.
Methods:
Six-week results from the olanzapine LAI study (N=404) were compared with those of 3 oral studies (study 1: olanzapine vs. haloperidol vs. placebo [N=335]; study 2: olanzapine vs. haloperidol vs. low-dose olanzapine [N=431]; study 3: olanzapine vs. placebo vs. low-dose olanzapine [N=152]). All patients had baseline Brief Psychiatric Rating Scale (BPRS) scores &gt;=24 (0-6 scale). Six-week effect sizes were calculated. Efficacy onset, pharmacokinetics, discontinuations, weight gain, and extrapyramidal symptoms were also assessed.
Results:
At 6 weeks, mean BPRS scores decreased by 14 to 15 points for olanzapine LAI (405 mg/4 weeks, 210 or 300 mg/2 weeks), by 8 to 16 for oral olanzapine (10+/-2.5 or 15+/-2.5 mg/day), and by 12 to 13 for haloperidol (15+/-5 mg/day). For those same dose groups, effect sizes vs. placebo for the BPRS were 0.7 to 0.8 for olanzapine LAI, 0.5 to 0.7 for oral olanzapine, and 0.6 for haloperidol. The first statistically significant separation from placebo on the BPRS occurred at 3 days for the olanzapine LAI groups and at 1 week for oral olanzapine and haloperidol (15+/-5 mg/day) in oral study 1 although as late as week 6 for the 10-mg/day olanzapine dose in oral study 3. Olanzapine concentrations were similar across studies. Weight gain &gt;=7% of baseline occurred in up to 35% of olanzapine LAI and oral patients versus up to 12% of haloperidol and placebo patients. Extrapyramidal symptoms were lowest in the olanzapine LAI groups and significantly greater in the haloperidol groups. No post-injection delirium/sedation syndrome events occurred in the olanzapine LAI study.
Conclusions:
Patients treated acutely with olanzapine LAI showed a similar pattern of improvement to that seen historically with oral olanzapine. With the exception of injection-related adverse events, the efficacy and tolerability profile of olanzapine LAI is similar to oral olanzapine.Trial RegistrationClinicalTrials.gov ID; URL: http//www.clinicaltrials.gov/: NCT00088478; ClinicalStudyResults.org ID; URL: http://www.clinicalstudyresults.org/: 917, 978, 982, and 5984.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/51</link>
                <dc:creator>Holland Detke</dc:creator>
                <dc:creator>Fangyi Zhao</dc:creator>
                <dc:creator>Michael Witte</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:51</dc:source>
        <dc:date>2012-05-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-51</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-51-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>51</prism:startingPage>
        <prism:publicationDate>2012-05-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/50">
        <title>Shame-proneness in attempted suicide patients</title>
        <description>Background:
It has been suggested that shame may be an important feature in suicidal behaviors. The disposition to react with shame, &quot;shame-proneness&quot;, has previously not been investigated in groups of attempted suicide patients. We examined shame-proneness in two groups of attempted suicide patients, one group of non-suicidal patients and one group of healthy controls. We hypothesized that the attempted suicide patients would be more shame-prone than non-suicidal patients and healthy controls.MethodThe Test of Self-Conscious Affect (TOSCA), which is the most used measure of shame-proneness, was completed by attempted suicide patients (n = 175: 105 women and 3 men with borderline personality disorder [BPD], 45 women and 22 men without BPD), non-suicidal psychiatric patients (n = 162), and healthy controls (n = 161). The participants were convenience samples, with patients from three clinical research projects and healthy controls from a fourth research project. The relationship between shame-proneness and attempted suicide was studied with group comparisons and multiple regressions. Men and women were analyzed separately.
Results:
Women were generally more shame-prone than men of the same participant group. Female suicide attempters with BPD were significantly more shame-prone than both female suicide attempters without BPD and female non-suicidal patients and controls. Male suicide attempters without BPD were significantly less shame-prone than non-suicidal male patients. In multiple regressions, shame-proneness was predicted by level of depression and BPD (but not by attempted suicide) in female patients, and level of depression and non-suicidality in male patients.
Conclusion:
Contrary to our hypothesis and related previous research, there was no general relationship between shame-proneness and attempted suicide. Shame-proneness was differentially related to attempted suicide in different groups of suicide attempters, with significantly high shame-proneness among female suicide attempters with BPD and a negative relationship between shame-proneness and attempted suicide among male patients. More research on state and trait shame in different groups of suicidal individuals seems clinically relevant.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/50</link>
                <dc:creator>Maria Wiklander</dc:creator>
                <dc:creator>Mats Samuelsson</dc:creator>
                <dc:creator>Jussi Jokinen</dc:creator>
                <dc:creator>Åsa Nilsonne</dc:creator>
                <dc:creator>Alexander Wilczek</dc:creator>
                <dc:creator>Gunnar Rylander</dc:creator>
                <dc:creator>Marie Åsberg</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:50</dc:source>
        <dc:date>2012-05-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-50</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-50-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>50</prism:startingPage>
        <prism:publicationDate>2012-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/49">
        <title>Emotional but not physical maltreatment is independently related to psychopathology in subjects with various degrees of social anxiety: a web-based Internet survey</title>
        <description>Background:
Previous studies reported that social phobia is associated with a history of child maltreatment. However, most of these studies focused on physical and sexual maltreatment whilst little is known about the specific impact of emotional abuse and neglect on social anxiety. We examined the association between emotional maltreatment, including parental emotional maltreatment as well as emotional peer victimization, and social anxiety symptoms in subjects with various degrees of social anxiety.
Methods:
The study was conducted as a web-based Internet survey of participants (N = 995) who had social anxiety symptoms falling within the high range, and including many respondents who had scores in the clinical range. The assessment included measures of child maltreatment, emotional peer victimization, social anxiety symptoms and general psychopathology.
Results:
Regression and mediation analyses revealed that parental emotional maltreatment and emotional peer victimization were independently related to social anxiety and mediated the impact of physical and sexual maltreatment. Subjects with a history of childhood emotional maltreatment showed higher rates of psychopathology than subjects with a history of physical maltreatment.
Conclusions:
Although our findings are limited by the use of an Internet survey and retrospective self-report measures, data indicated that social anxiety symptoms are mainly predicted by emotional rather than physical or sexual types of victimization.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/49</link>
                <dc:creator>Benjamin Iffland</dc:creator>
                <dc:creator>Lisa Sansen</dc:creator>
                <dc:creator>Claudia Catani</dc:creator>
                <dc:creator>Frank Neuner</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:49</dc:source>
        <dc:date>2012-05-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-49</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-49-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>49</prism:startingPage>
        <prism:publicationDate>2012-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/48">
        <title>Effect of a psycho-educational intervention for family members on caregiver burdens and psychiatric symptoms in patients with schizophrenia in Shiraz, Iran</title>
        <description>Background:
This study explored the effectiveness of family psycho-education in reducing patients&apos; symptoms and on family caregiver burden.
Methods:
Seventy Iranian outpatients with a diagnosis of schizophrenia disorder and their caregivers were randomly allocated to the experimental (n = 35) or control groups (n = 35). Patients in the experimental group received antipsychotic drug treatment and a psycho-educational program was arranged for their caregivers. The psycho-educational program consisted of ten 90-min sessions held during five weeks (two session in each week). Each caregiver attended 10 sessions (in five weeks) At baseline, immediately after intervention, and one month later. Validated tools were used to assess patients&apos; clinical status and caregiver burden.
Results:
Compared with the control group, the case group showed significantly reduced symptom severity and caregiver burden both immediately after intervention and one month later.
Conclusions:
These results suggest that even need based short-term psycho-educational intervention for family members of Iranian patients with schizophrenic disorder may improve the outcomes of patients and their families.Trial registrationIRCT Number:138809122812 N1`</description>
        <link>http://www.biomedcentral.com/1471-244X/12/48</link>
                <dc:creator>Farkhondeh Sharif</dc:creator>
                <dc:creator>Maryam Shaygan</dc:creator>
                <dc:creator>Arash Mani</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:48</dc:source>
        <dc:date>2012-05-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-48</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-48-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>48</prism:startingPage>
        <prism:publicationDate>2012-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/47">
        <title>Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes</title>
        <description>Background:
Carbamazepine (CBZ) has been used in the treatment of bipolar disorder, both in acute mania and maintenance therapy, since the early 1970s. Here, we report a follow-up study of CBZ-treated bipolar patients in the Taipei City Psychiatric Centre.
Methods:
Bipolar patients diagnosed according to the DSM-IV system and treated with CBZ at the Taipei City Psychiatric Centre had their charts reviewed to evaluate the efficacy and side effects of this medication during an average follow-up period of 10 years.
Results:
A total of 129 bipolar patients (45 males, mean age: 45.7 +/- 10.9 year) were included in the analysis of CBZ efficacy used alone (n = 63) or as an add-on after lithium (n = 50) or valproic acid (n = 11), or the both of them (n = 5). The mean age of disease onset was 24.6 +/- 9.5 years. The mean duration of CBZ use was 10.4 +/- 5.2 year. The mean dose used was 571.3 +/- 212.6 mg/day with a mean plasma level of 7.8 +/- 5.9 ug/mL. Mean body weight increased from 62.0 +/- 13.4 kg to 66.7 +/- 13.1 kg during treatment. The frequencies of admission per year before and after CBZ treatment were 0.33 +/- 0.46 and 0.14 +/- 0.30, respectively. The most common side effects targeted the central nervous system (24%), including dizziness, ataxia and cognitive impairment. Other common side effects were gastrointestinal disturbances (3.6%), tremor (3.6%), skin rash (2.9%), and blurred vision (2.9%). Eighty-eight patients (68.2%) were taking antipsychotics concomitantly. Ninety-six patients (74.4%) needed to use benzodiazepines concomitantly. Sixty-three (48.8%) patients had zero episodes in a 10-year follow-up period, compared to all patients having episodes prior to treatment. Using variable analysis, we found better response to CBZ in males than in females.
Conclusions:
CBZ is efficacious in the maintenance treatment of bipolar disorder in naturalistic clinical practice, either as monotherapy or in combination with other medications. CBZ is well tolerated by most patients in this patient group.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/47</link>
                <dc:creator>Chia-Hui Chen</dc:creator>
                <dc:creator>Shih-Ku Lin</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:47</dc:source>
        <dc:date>2012-05-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-47</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-47-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>47</prism:startingPage>
        <prism:publicationDate>2012-05-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/12/46">
        <title>Service suspension for mental disorders in armed forces draftees in the Penghu area</title>
        <description>Background:
It is important to monitor draftees for mental disorders before or at an early stage of military service. The aim of this study was to characterize the draftees who were suspended from service for mental disorders among draftees in a high readiness military zone in the Taiwan Strait.MethodA total of 152 draftees consulted the outpatient service of the Department of Psychiatry at Penghu branch, Tri-Service General Hospital in Taiwan during the period between August 2004 and July 2008, and whose severity of mental disorder fit the criteria for service suspension were recruited as the study group (SG). Draftees who had adjusted normally were the control group (CG).
Results:
The major causes for suspension were major depressive disorders and personality disorders. In the study group, the number of draftees seeking psychiatric outpatient treatment increased from 49.3% before service to 100% during service. In addition, higher rates of suicidal ideation, suicide plans, attempted suicide, and homicidal ideation were found in the study group than in the control group. The percentages of draftees who were unwilling  to serve and absent without official leave (AWOL) during military service in Penghu were also significantly higher in the study group than in the control group.
Conclusions:
Based on the characteristics of  the draftees who were suspended from service for mental disorders, psychological factors such as suicidal ideation, suicide attempts and adjustment disorders should be surveyed and monitored before the draft and at an early stage of military service.</description>
        <link>http://www.biomedcentral.com/1471-244X/12/46</link>
                <dc:creator>Chuang-Wei Chen</dc:creator>
                <dc:creator>Chin-Han Kao</dc:creator>
                <dc:creator>Chih-Kang Chen</dc:creator>
                <dc:creator>Chia-He Peng</dc:creator>
                <dc:creator>Wu-Hsi Wang</dc:creator>
                <dc:source>BMC Psychiatry 2012, null:46</dc:source>
        <dc:date>2012-05-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-12-46</dc:identifier>
                                <prism:require>/content/figures/1471-244X-12-46-toc.gif</prism:require>
                <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>46</prism:startingPage>
        <prism:publicationDate>2012-05-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

